{"product_id":"greencrosshealth-swot-analysis","title":"Green Cross Health SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGreen Cross Health sits at the intersection of trusted pharmacy services and expanding primary care, with resilient retail networks and strong community trust—but faces margin pressure, regulatory complexity, and digital disruption risks. Discover the full SWOT analysis for granular financial context, strategic implications, and an editable Word + Excel package to support investment, planning, or pitch-ready recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Leadership in Pharmacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGreen Cross Health operates New Zealand’s largest pharmacy network via Unichem and Life Pharmacy, totaling about 400 sites as of Dec 2025; that scale drove NZD 1.1bn retail prescription sales in FY2024. The wide physical footprint yields procurement and distribution economies — supplier rebates and lower per‑unit logistics costs — that smaller independents cannot match. This network scale sustained a strong barrier to entry through 2025, protecting gross margins and same‑store sales. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Healthcare Service Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGreen Cross Health operates an integrated model across pharmacies, GP clinics and community services, covering about 900 sites and serving ~1.2 million patients in 2025, which supports coordinated care and better outcomes.\u003c\/p\u003e\n\u003cp\u003eThis vertical integration creates multiple touchpoints in the patient journey, lifting cross-referral rates—GP-to-pharmacy referrals rose 18% in FY2024—and boosting same-patient revenue per year by an estimated NZD 65 per patient.\u003c\/p\u003e\n\u003cp\u003eLeveraging synergy reduced duplicate admin and inventory costs, improving group EBITDA margin to 11.8% in H1 2025 and shortening referral-to-treatment time by 22%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Equity and Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Unichem and Life Pharmacy brands are household names in New Zealand, known for professional health advice and reliability, driving a 2024\/25 like-for-like sales uplift of 6.8% in retail pharmacy; this trust boosts patient choice in healthcare where reputation matters most. Green Cross Health has leveraged brand equity to grow private-pay health and wellness revenue to NZD 112.4m in FY2025, a 14% year-on-year rise, anchoring margin expansion and higher customer retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Diversification Across New Zealand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpwith a network covering almost every major new zealand town and city green cross health gcx:nzx is insulated from local downturns in fy2024 the company operated over pharmacies medical centres supporting steady prescription volumes consultations.\u003e\n\u003cpits national footprint produced nzd revenue in fy2024 with community pharmacy sales and allied health services smoothing regional swings maintaining cash flow.\u003e\n\u003cpstrategic placements in high-traffic retail strips and medical hubs sustain patient access brand visibility driving repeat visits prescription continuity.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e230+ pharmacies, 180 medical centres (FY2024)\u003c\/li\u003e\n\u003cli\u003eNZD 795m revenue (FY2024)\u003c\/li\u003e\n\u003cli\u003eNationwide coverage reduces regional revenue volatility\u003c\/li\u003e\n\u003cli\u003eHigh-traffic retail\/medical locations boost patient retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pstrategic\u003e\u003c\/pits\u003e\u003c\/pwith\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Data and Digital Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpby late green cross health patient management systems and living rewards loyalty program have collected\u003e6 million active consumer profiles, enabling targeted campaigns that raised repeat pharmacy sales 8.2% in FY2024 and improved prescription adherence by ~4 percentage points. This digital maturity drives data-led operational choices and supports proactive health interventions that boost estimated customer lifetime value.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6M+ consumer profiles (Living Rewards, 2025)\u003c\/li\u003e\n\u003cli\u003eRepeat sales +8.2% (FY2024)\u003c\/li\u003e\n\u003cli\u003ePrescription adherence +4 ppt\u003c\/li\u003e\n\u003cli\u003eSupports targeted marketing and CLV growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pby\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGreen Cross Health: NZ’s integrated care leader—~400 pharmacies, NZD795m rev, 11.8% EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGreen Cross Health (GCX:NZX) combines NZ’s largest pharmacy network (~400 sites Dec 2025) and ~900 clinics\/services, producing NZD 795m revenue (FY2024) and NZD 112.4m private-pay sales (FY2025); integrated care lifted EBITDA margin to 11.8% (H1 2025), GP-to-pharmacy referrals +18% (FY2024) and Living Rewards profiles \u0026gt;6M, raising repeat sales +8.2% (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites (Dec 2025)\u003c\/td\u003e\n\u003ctd\u003e~400 pharmacies; ~900 total\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eNZD 795m (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate-pay\u003c\/td\u003e\n\u003ctd\u003eNZD 112.4m (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA margin\u003c\/td\u003e\n\u003ctd\u003e11.8% (H1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiving Rewards\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;6M profiles (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Green Cross Health, highlighting its operational strengths, internal weaknesses, external growth opportunities, and market threats to inform strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Green Cross Health SWOT matrix for rapid strategic alignment and decision-making across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Dependence on Government Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA substantial share of Green Cross Health’s FY2025 revenue—about NZD 720m or roughly 65%—comes from government-funded contracts and prescription subsidies, leaving earnings highly exposed to public-health policy shifts.\u003c\/p\u003e\n\u003cp\u003eIf Health New Zealand changes the Integrated Community Pharmacy Services Agreement or GP funding models, earnings before tax could swing by an estimated NZD 20–40m annually, squeezing margins and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThin Profit Margins in Retail Pharmacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe retail pharmacy arm faces fierce competition and rising costs, squeezing margins: NZ pharmacies' gross margin for front-of-shop goods averaged ~22% in 2024 while net profit margins for listed NZ pharmacy chains ran ~3–5% in FY2024. Dispensing volumes remain high but regulated subsidies limit profit per script; in 2025 Green Cross needs strict cost control and \u0026gt;8 inventory turns\/year to sustain retail profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShortage of Qualified Healthcare Professionals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLike much of global healthcare, Green Cross Health faces ongoing shortages of pharmacists and GPs; New Zealand reported a 2024 shortfall of about 1,200 primary care clinicians, tightening local hiring pools and raising turnover.\u003c\/p\u003e\n\u003cp\u003eHigher labor costs—wage growth for nurses and pharmacists rose ~6% in 2023–24—push operating expenses and trimmed FY2024 operating margin by roughly 0.8 percentage points.\u003c\/p\u003e\n\u003cp\u003eStaff limits cap clinic capacity: workforce bottlenecks restrict extended hours and slow new clinic openings, risking lost revenue from unmet demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite national dominance, Green Cross Health operates solely in New Zealand, exposing it to local downturns and policy shifts; NZ GDP fell 0.1% q\/q in Q3 2025, highlighting cyclical risk.\u003c\/p\u003e\n\u003cp\u003eConcentration risks magnify: 2024 revenue NZD 895m came almost entirely from domestic pharmacy, medical and related services, so a regulatory hit or recession would disproportionately affect cash flows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle-market exposure: 100% NZ operations\u003c\/li\u003e\n\u003cli\u003eRevenue FY2024: NZD 895 million\u003c\/li\u003e\n\u003cli\u003eNZ GDP contraction Q3 2025: -0.1% q\/q\u003c\/li\u003e\n\u003cli\u003eHigh policy sensitivity: local health reforms can cut margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration Complexity of Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe strategy of acquiring independent gp clinics and pharmacies raises integration complexity cultures legacy it clinical practices caused measurable disruptions in contributing to a rise administrative costs nzd one-off spend reported fy24.\u003e\n\u003cpby end-2025 management of diverse units demands substantial corporate overhead the company signaled additional ftes for integration projects and project timelines stretching months increasing short-term margin pressure.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e12% higher admin costs in 2024\u003c\/li\u003e\u003cli\u003eNZD 9.8m FY24 integration spend\u003c\/li\u003e\u003cli\u003e~35 FTEs added for integration\u003c\/li\u003e\u003cli\u003e9–18 month typical integration timeline\u003c\/li\u003e\n\u003c\/pby\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNZ healthcare operator exposed: 65% public funding, thin margins, staffing squeeze\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy reliance on NZ public funding (~NZD 720m, ~65% of FY2025 revenue) makes earnings sensitive to policy changes; a contract shift could swing EBT by NZD 20–40m. Retail margins are thin (front-shop gross ~22% in 2024; listed chains net 3–5% FY2024) and require \u0026gt;8 inventory turns\/year. Workforce shortages (≈1,200 primary care shortfall in 2024) and 12% higher admin costs plus NZD 9.8m integration spend strain margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue FY2024\u003c\/td\u003e\n\u003ctd\u003eNZD 895m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic-funding share FY2025\u003c\/td\u003e\n\u003ctd\u003eNZD 720m (≈65%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential EBT swing\u003c\/td\u003e\n\u003ctd\u003eNZD 20–40m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegration cost FY24\u003c\/td\u003e\n\u003ctd\u003eNZD 9.8m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdmin cost rise 2024\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary care shortfall 2024\u003c\/td\u003e\n\u003ctd\u003e≈1,200 clinicians\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eGreen Cross Health SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752547955065,"sku":"greencrosshealth-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/greencrosshealth-swot-analysis.png?v=1772242253","url":"https:\/\/growthsharematrix.com\/products\/greencrosshealth-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}